Study S001739

Comprehensive Clinical Evaluation Study of GLP-1RA

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06686134
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 492
Start: 2024-07-01
Primary completion: 2025-12-31
Lead sponsor: LI YAN
Conditions: T2DM
Results posted: FALSE

Registered primary outcomes

HbA1c compliance rate [4, 8, 12, and 16 weeks after the start of medication]
Weight reduction from baseline [4, 8, 12, and 16 weeks after the start of medication]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014565	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Pratley RE, The lancet. Diabetes & endocrinology	2018	Randomized trial	PMID 29397376 DOI	registry reference RESULT:29397376